Lilly budgets $1.2B for GLP-1 pill factory in Puerto Rico
Eli Lilly is making another move to help boost production for its oral GLP-1 franchise, with a new $1.2 billion factory in Puerto Rico. Construction for the facility dedicated to make orforglipron will
Walmart to offer in-store pickup for Zepbound
Eli Lilly and Walmart have partnered to offer in-store pickup of Zepbound (tirzepatide) single-dose vials through the LillyDirect platform by mid-November. The collaboration marks the first time patients using LillyDirect, the company’s direct-to-consumer healthcare platform, will be able to access self-pay pricing for Zepbound vials at a retail pharmacy, according to an Oct. 29 news […]
Obesity on decline in US as GLP-1 use skyrockets: Gallup
The obesity rate in the U.S. has seen a marked decline over the last three years, as the share of Americans who report using GLP-1 agonists for weight loss skyrockets, according to data from Gallup. In the latest report from the Gallup National Health and Well-Being Index, published Tuesday, 37 percent of American adults are…
Cardioprotective Effects of Semaglutide Independent of Adiposity
WEDNESDAY, Oct. 29, 2025 — The cardioprotective effects of semaglutide are independent of baseline adiposity and weight loss, according to a study published online Oct. 22 in The Lancet.
John Deanfield, M.B., B.Chir., from University College…
The Hidden Toll of GLP-1 Care Complexity on PCPs
An obesity medicine specialist’s thoughts on reducing the burden of prior authorization, documentation, and follow-ups. Medscape Medical News
AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists
De novo GLP-1RAs can be computationally designed to exhibit extended half-life and superior efficacy compared to Semaglutide. Abstract Peptide drugs have revolutionized modern therapeutics, offering novel treatment avenues for various diseases. Nevertheless, low design efficacy, time consumption, and high cost still hinder peptide drug design and discovery. Here, an efficient approach that integrates deep learning-based […]
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
Key Points BioAge Labs is developing a promising weight management candidate. The medicine could have several advantages over approved anti-obesity drugs. However, BioAge is an early-stage biotech whose prospects still look incredibly risky. 10 stocks we like better than BioAge Labs › Biotech investors have been closely monitoring the weight management space over the past […]
Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta‐analysis of randomized controlled trials
Abstract Aims To investigate the renal outcomes of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose transport protein-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus (T2DM) with chronic renal disease (CKD). Materials and Methods PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched through July 2025 for randomized controlled trials […]
Effectiveness and safety of GLP‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
Abstract Aims Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real-world effectiveness and safety of GLP-1 RAs in this population. Materials and Methods CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated with one or more GLP-1 RAs across […]
What do Rollerblades and Ozempic have in common?
What do Rollerblades and Ozempic have in common? Host Alex Hogan explains in the latest episode of STATus Report.